ARS Pharmaceuticals, Inc. (SPRY): Shareholders' Equity
$114.26M
As of 2025-12-31
$12.51M
As of 2026-06-30
-25.2%
3-year compound annual growth
-21.5%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $114.26M | -55.5% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $256.80M | +11.3% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $230.76M | -15.4% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $272.89M | n/m | 2024-03-21, Balance as of period end |
| 2021-12-31 | -$31.27M | n/m | 2023-03-23, Balance as of period end |
| 2020-12-31 | $382.88M | n/a | 2022-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $114.26M | -55.5% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $538.75M | +2.2% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $424.29M | -10.1% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $213.99M | -11.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$185.83M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$659.62M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $26.15M | +7.1% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $99.01M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $966.90M | -8.4% |
Compare SPRY, NRIX, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗